메뉴 건너뛰기




Volumn 607, Issue 1-3, 2009, Pages 35-40

Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors

Author keywords

Antipsychotic; Aripiprazole; Dopamine D2 receptor; Partial agonist; Receptor reserve; Schizophrenia

Indexed keywords

4' ACETYL N [4 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]BUTYL]BIPHENYL 4 CARBOXAMIDE; ARIPIPRAZOLE; BIFEPRUNOX; BP 897; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PARTIAL AGONIST; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

EID: 62249199785     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.02.007     Document Type: Article
Times cited : (36)

References (31)
  • 2
    • 34347335477 scopus 로고    scopus 로고
    • The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study
    • Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., and Khan A. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68 (2007) 843-853
    • (2007) J. Clin. Psychiatry , vol.68 , pp. 843-853
    • Berman, R.M.1    Marcus, R.N.2    Swanink, R.3    McQuade, R.D.4    Carson, W.H.5    Corey-Lisle, P.K.6    Khan, A.7
  • 7
    • 6344253360 scopus 로고    scopus 로고
    • Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management
    • Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
    • (2004) Drugs , vol.64 , pp. 2291-2314
    • Haddad, P.M.1    Wieck, A.2
  • 8
    • 0036738786 scopus 로고    scopus 로고
    • Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    • Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 (2002) 763-771
    • (2002) J. Clin. Psychiatry , vol.63 , pp. 763-771
    • Kane, J.M.1    Carson, W.H.2    Saha, A.R.3    McQuade, R.D.4    Ingenito, G.G.5    Zimbroff, D.L.6    Ali, M.W.7
  • 10
    • 0034025771 scopus 로고    scopus 로고
    • 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia
    • 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
    • (2000) Am. J. Psychiatry , vol.157 , pp. 514-520
    • Kapur, S.1    Zipursky, R.2    Remington, G.3    Houle, S.4
  • 11
    • 0038585981 scopus 로고    scopus 로고
    • A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania
    • Keck P.E.J., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., and Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am. J. Psychiatry 160 (2003) 1651-1658
    • (2003) Am. J. Psychiatry , vol.160 , pp. 1651-1658
    • Keck, P.E.J.1    Marcus, R.2    Tourkodimitris, S.3    Ali, M.4    Liebeskind, A.5    Saha, A.6    Ingenito, G.7
  • 16
  • 18
    • 40949089056 scopus 로고    scopus 로고
    • The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study
    • Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., Trivedi M.H., Thase M.E., and Berman R.M. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28 (2008) 156-165
    • (2008) J. Clin. Psychopharmacol. , vol.28 , pp. 156-165
    • Marcus, R.N.1    McQuade, R.D.2    Carson, W.H.3    Hennicken, D.4    Fava, M.5    Simon, J.S.6    Trivedi, M.H.7    Thase, M.E.8    Berman, R.M.9
  • 21
    • 16644402581 scopus 로고    scopus 로고
    • A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study
    • McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., and Carson W.H. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry 65 (2004) 47-56
    • (2004) J. Clin. Psychiatry , vol.65 , pp. 47-56
    • McQuade, R.D.1    Stock, E.2    Marcus, R.3    Jody, D.4    Gharbia, N.A.5    Vanveggel, S.6    Archibald, D.7    Carson, W.H.8
  • 22
    • 38049005307 scopus 로고    scopus 로고
    • Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis
    • Miller D.D., Eudicone J.M., Pikalov A., and Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry 68 (2007) 1901-1906
    • (2007) J. Clin. Psychiatry , vol.68 , pp. 1901-1906
    • Miller, D.D.1    Eudicone, J.M.2    Pikalov, A.3    Kim, E.4
  • 25
    • 0038488945 scopus 로고    scopus 로고
    • Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder
    • Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 (2003) 681-690
    • (2003) Arch. Gen. Psychiatry , vol.60 , pp. 681-690
    • Potkin, S.G.1    Saha, A.R.2    Kujawa, M.J.3    Carson, W.H.4    Ali, M.5    Stock, E.6    Stringfellow, J.7    Ingenito, G.8    Marder, S.R.9
  • 26
    • 0030271402 scopus 로고    scopus 로고
    • Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study
    • Semba J., Sakai M., Miyoshi R., Mataga N., Fukamauchi F., and Kito S. Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem. Int. 29 (1996) 435-442
    • (1996) Neurochem. Int. , vol.29 , pp. 435-442
    • Semba, J.1    Sakai, M.2    Miyoshi, R.3    Mataga, N.4    Fukamauchi, F.5    Kito, S.6
  • 27
    • 20344400385 scopus 로고    scopus 로고
    • Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic
    • Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., and Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515 (2005) 10-19
    • (2005) Eur. J. Pharmacol. , vol.515 , pp. 10-19
    • Tadori, Y.1    Miwa, T.2    Tottori, K.3    Burris, K.D.4    Stark, A.5    Mori, T.6    Kikuchi, T.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.